Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Insider Sells $219,000.00 in Stock

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRAGet Free Report) insider Helen Louise Collins sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total transaction of $219,000.00. Following the completion of the transaction, the insider directly owned 25,000 shares of the company’s stock, valued at $1,095,000. This represents a 16.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Louise Collins also recently made the following trade(s):

  • On Friday, April 17th, Helen Louise Collins sold 5,000 shares of Bitwise MARA Option Income Strategy ETF stock. The stock was sold at an average price of $47.67, for a total transaction of $238,350.00.
  • On Wednesday, March 25th, Helen Louise Collins sold 40,000 shares of Bitwise MARA Option Income Strategy ETF stock. The shares were sold at an average price of $35.10, for a total transaction of $1,404,000.00.

Bitwise MARA Option Income Strategy ETF Stock Down 3.2%

IMRA opened at $17.03 on Thursday. The stock has a fifty day moving average of $16.69 and a 200-day moving average of $15.74. The firm has a market capitalization of $3.24 million, a P/E ratio of 340.60 and a beta of 2.88. Bitwise MARA Option Income Strategy ETF has a 12-month low of $11.99 and a 12-month high of $54.94.

Bitwise MARA Option Income Strategy ETF Company Profile

(Get Free Report)

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2?related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.

Featured Stories

Insider Buying and Selling by Quarter for Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA)

Receive News & Ratings for Bitwise MARA Option Income Strategy ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bitwise MARA Option Income Strategy ETF and related companies with MarketBeat.com's FREE daily email newsletter.